BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 4.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,979,992 shares of the biotechnology company's stock after buying an additional 91,998 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.96% of BioCryst Pharmaceuticals worth $14,890,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. The Manufacturers Life Insurance Company lifted its stake in BioCryst Pharmaceuticals by 40.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company's stock valued at $2,274,000 after acquiring an additional 86,571 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of BioCryst Pharmaceuticals by 1,058.1% during the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company's stock valued at $3,127,000 after purchasing an additional 375,890 shares during the period. Fisher Asset Management LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 16.9% in the third quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company's stock worth $25,369,000 after buying an additional 481,359 shares in the last quarter. Geode Capital Management LLC boosted its holdings in BioCryst Pharmaceuticals by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company's stock valued at $36,776,000 after purchasing an additional 127,708 shares during the period. Finally, BNP Paribas Financial Markets boosted its stake in BioCryst Pharmaceuticals by 472.0% during the third quarter. BNP Paribas Financial Markets now owns 496,784 shares of the biotechnology company's stock valued at $3,776,000 after buying an additional 409,938 shares during the period. 85.88% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

BCRX has been the subject of a number of research reports. Evercore ISI upped their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a report on Monday, January 13th. Needham & Company LLC increased their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a "buy" rating in a research report on Monday, January 13th. Wedbush started coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price objective on the stock. JMP Securities reiterated a "market outperform" rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Finally, Royal Bank of Canada restated an "outperform" rating and set a $11.00 price target (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $15.57.

BioCryst Pharmaceuticals Trading Up 0.9 %

BioCryst Pharmaceuticals stock traded up $0.07 during trading hours on Monday, hitting $8.05. 3,480,409 shares of the stock traded hands, compared to its average volume of 2,756,781. BioCryst Pharmaceuticals, Inc. has a one year low of $4.03 and a one year high of $9.50. The firm's 50-day moving average price is $8.12 and its two-hundred day moving average price is $7.82. The company has a market cap of $1.68 billion, a PE ratio of -13.20 and a beta of 1.85.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to the consensus estimate of $126.64 million. The firm's revenue for the quarter was up 40.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.28 EPS. On average, sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.